ClinicalTrials.gg
RecruitingNCT05447208Updated Feb 12, 2025

Effect of GH on the Blastocyst Euploid Rate in AMA Patients

A Phase 3 interventional study of Growth Hormone and GnRH antagonist in Preimplantation Genetic Testing, Growth Hormone and Age, Parental, sponsored by ShangHai Ji Ai Genetics & IVF Institute. Recruiting at 1 site in China. Open to female participants aged 38 Years and older. Per ClinicalTrials.gov, last updated 2025-02-12.

Sponsored by ShangHai Ji Ai Genetics & IVF Institute · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Aug 2022; still recruiting 4 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
38 Years and older
Sex
Female
01

Study summary

This randomized trial aims to compare the euploid rate of blastocysts in AMA patients undergoing PGT-A (preimplantation genetic testing for aneuploidy) with or without growth hormone supplement.

Infertile patients ≥38 years old will be recruited for study after informed consent if they fulfill the inclusion criteria and do not have the exclusion criteria. Eligible women will be randomised into one of the two groups:

Treatment group: Women will receive growth hormone (GH) supplement before and during antagonist protocol for ovarian stimulation.

Control group: Women will receive antagonist protocol for ovarian stimulation. The primary outcome is the euploidy rate of blastocysts.

02

Conditions studied

  • Preimplantation Genetic Testing
  • Growth Hormone
  • Age, Parental
03

In context

Lead sponsor

ShangHai Ji Ai Genetics & IVF Institute is the lead sponsor of 26 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
38 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥38; intended to undergo PGT-A
  • in the normal range (18.50-24.0kg/m2)
  • Normal semen analysis for the male partner

Exclusion criteria

Exclusion Criteria:

  • Endometriosis grade 3 or higher, untreat hydrosalpinx
  • Women with a uterine cavity abnormality, such as a uterine congenital malformation (uterus uni-cornate, bicornate, or duplex); untreated uterine septum, adenomyosis, submucous myoma, or endo-metrial polyp(s)
  • Women who are indicated and planned to undergo PGT-SR (Preimplantation genetic testing for structural rearrangement) or PGT-M (Preimplantation genetic testing for monogenic disorder), for example, parental abnormal karyo-type or diagnosed with monogenic disease
  • History of endocrine disorder, diseases or diagnosed thrombophilia
  • History of GH supplementation in the previous IVF treatment or taking other supplementary drugs used during stimulation; patients with absolute or relative to GH treatment, including active or history of cancer, diabetic retinopathy, diabetes mellitus, and chronic kidney disease.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Treatment group

    GH is supplemented during ovarian stimulation

    Drug: Growth Hormone · Drug: GnRH antagonist

  • Active comparator
    Control group

    GH is not supplemented during ovarian stimulation.

    Drug: GnRH antagonist

Interventions

06

What researchers measure

Primary outcomes

  1. euploidy rate

    euploidy rate of blastocysts

    Time frame: 1 month after oocyte retrieval

Secondary outcomes

  1. live birth rate

    deliveries ≥22 weeks gestation with heartbeat and breath of the first frozen embryo transfer

    Time frame: 1 year after embryo transfer

  2. cumulative live birth rate

    cumulative live birth within 6 months of randomization

    Time frame: 1 year after embryo transfer

  3. ongoing pregnancy

    a viable pregnancy beyond 12 weeks' gestation of the first frozen embryo transfer

    Time frame: 12 weeks' gestation

  4. clinical pregnancy rate

    the presence of intrauterine gestational sac by transvaginal ultrasound at 6 gestational weeks of the first frozen embryo transfer

    Time frame: 6 weeks after embryo transfer

  5. number of euploid blastocysts in an OS cycle

    the number of blastocysts acquired in an ovarian stimulation cycle that are identified as euploid by PGT-A

    Time frame: 1 month after oocyte retrieval

  6. the probability of obtaining euploid blastocysts in an OS cycle

    If the ovarian stimulation cycle produces euploid blastocysts, the result is 1; if not, it's 0. Mean values will be calculated for the two groups.

    Time frame: 1 month after oocyte retrieval

  7. KIDScore of euploid embryos

    an AI-driven embryo score generated through the EmbryoViewer software relying on kinetic parameters and associated with embryo implantation potential

    Time frame: 6 days after oocyte retrieval

07

Study locations

1 of 1 sites recruiting
  • Shanghai JIAI Genetics and IVF Institute
    Shanghai, Shanghai 200011, China
    Recruiting
08

References and documents

Publications

  • Demko ZP, Simon AL, McCoy RC, Petrov DA, Rabinowitz M. Effects of maternal age on euploidy rates in a large cohort of embryos analyzed with 24-chromosome single-nucleotide polymorphism-based preimplantation genetic screening. Fertil Steril. 2016 May;105(5):1307-1313. doi: 10.1016/j.fertnstert.2016.01.025. Epub 2016 Feb 8. PubMed 26868992 ↗
  • Weall BM, Al-Samerria S, Conceicao J, Yovich JL, Almahbobi G. A direct action for GH in improvement of oocyte quality in poor-responder patients. Reproduction. 2015 Feb;149(2):147-54. doi: 10.1530/REP-14-0494. Epub 2014 Nov 5. PubMed 25376626 ↗
  • Gong Y, Luo S, Fan P, Jin S, Zhu H, Deng T, Quan Y, Huang W. Growth hormone alleviates oxidative stress and improves oocyte quality in Chinese women with polycystic ovary syndrome: a randomized controlled trial. Sci Rep. 2020 Oct 30;10(1):18769. doi: 10.1038/s41598-020-75107-4. PubMed 33127971 ↗
  • Liu C, Li S, Li Y, Tian J, Sun X, Song T, Yan G, Ding L, Sun H. Growth hormone ameliorates the age-associated depletion of ovarian reserve and decline of oocyte quality via inhibiting the activation of Fos and Jun signaling. Aging (Albany NY). 2021 Feb 17;13(5):6765-6781. doi: 10.18632/aging.202534. Epub 2021 Feb 17. PubMed 33621201 ↗
  • Skillern A, Leonard W, Pike J, Mak W. Growth hormone supplementation during ovarian stimulation improves oocyte and embryo outcomes in IVF/PGT-A cycles of women who are not poor responders. J Assist Reprod Genet. 2021 May;38(5):1055-1060. doi: 10.1007/s10815-021-02088-2. Epub 2021 Feb 3. PubMed 33534048 ↗
  • Regan SLP, Knight PG, Yovich JL, Arfuso F, Dharmarajan A. Growth hormone during in vitro fertilization in older women modulates the density of receptors in granulosa cells, with improved pregnancy outcomes. Fertil Steril. 2018 Dec;110(7):1298-1310. doi: 10.1016/j.fertnstert.2018.08.018. PubMed 30503129 ↗

Individual participant data

Plan to share: Yes

Supporting information: Study protocol

Time frame: Data will be available when beginning 3 months and ending 5 years following article publication

Access criteria: To achieve aims in the approved proposal, researchers who provide a methodologically sound proposal will be shared with. Proposals should be sent to 08301010255@fudan.edu.cn.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2022 (actual). Primary completion is estimated for Mar 2026, 43 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2022
First posted
Jul 7, 2022
StartActual
Aug 1, 2022
Primary completionEst.
Mar 1, 2026
CompletionEst.
Dec 31, 2026
Last update
Feb 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05447208
Lead sponsor
ShangHai Ji Ai Genetics & IVF Institute
Responsible party
Sponsor
First posted
Jul 7, 2022
Start date
Aug 1, 2022
Primary completion
Mar 1, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Feb 12, 2025

Study contacts

YILUN SUI, MD
Contact
08301010255@fudan.edu.cn
86-13661553127
XIAOXI SUN, PhD
Contact
XIAOXI SUN, PhD
principal investigator · Shanghai JiAi Genetics & IVF Institute, China

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Growth Hormone

Start the discussion